Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

FDA approves Tesaro’s ovarian cancer drug

Written by: | no-reply@reuters.com | Dated: Monday, March 27th, 2017

 

The U.S. Food and Drug Administration on Monday approved Tesaro Inc’s drug, niraparib, for the treatment of recurrent ovarian cancer.

Epithelial ovarian, fallopian tube or primary peritoneal cancer affects the tissue covering the ovary or lining of the fallopian tube or abdominal wall.

 

(Reporting by Akankshita Mukhopadhyay in Bengaluru)

 

Reuters source:

http://www.reuters.com/article/us-tesaro-fda-idUSKBN16Y2G2

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!

Subscribe

Ad Right Bottom